Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer. Its pipeline centers on proprietary immunomodulatory drug candidates such as rezpegaldesleukin, NKTR-255 and NKTR-0165, while much of its historical revenue came from collaborations, royalties and licensing arrangements rather than marketed products.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in autoimmune disease and cancer that are being advanced through preclinical and clinical development.
Upfront fees, milestones and other contingent payments from pharma and biotech partners.
Non-cash and cash royalty streams tied to partnered products developed using Nektar technology.
Historical product sales from fixed-price manufacturing and supply arrangements with collaborators.
PEGylation and polymer conjugate technologies licensed to partners for drug development and commercialization.
Products
Reported · share of revenue- Non Cash Royalty Revenue Related to Sale of Future Royalties99.5 %
- License Collaboration and Other Revenue0.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Nektar’s direct customers are primarily pharmaceutical and biotechnology collaboration partners that license its technology, fund development, or commercialize partnered assets. Indirectly, its end markets are patients and physicians in autoimmune disease and oncology, but the company currently has no marketed products of its own. Revenue depends on partner decisions, clinical progress and the ability to secure new collaboration agreements.
Large and mid-sized pharma companies that license Nektar’s assets or technology and pay milestones, royalties or supply fees.
Biotech companies that co-develop or in-license immunology assets and use Nektar’s platform to advance candidates.
Hospitals, investigators and CROs that support patient enrollment, clinical operations and regulatory development.
Physicians and patients in autoimmune disease and oncology who would use approved products if programs succeed.
Strategy
Nektar is prioritizing advancement of its internal immunotherapy pipeline, especially rezpegaldesleukin, while seeking to rebuild collaboration revenue after the termination of the Eli Lilly agreement. The company is also trying to preserve optionality through new partnerships, because its business model depends on external funding, clinical validation and eventual commercialization support. Capital preservation and pipeline focus are central to its near-term strategy.
It is the lead asset and the main driver of future value creation and partnering interest.
The company lost collaboration-based revenue after the Eli Lilly termination and needs external funding support.
Multiple shots on goal reduce dependence on a single asset and improve long-term partnering value.
As a clinical-stage company without marketed products, liquidity and burn management are critical.
Geography
Nektar is headquartered in the United States and its business is tied to U.S. clinical development, regulatory oversight and capital markets. Its historical partnered products and royalty streams have also had exposure to Europe and other international markets through global commercialization by partners, but the company itself currently has no disclosed country-level revenue mix. Operationally, the business is concentrated in research, development and collaboration management rather than manufacturing scale.
Risks
Nektar’s value is highly dependent on clinical success, especially for rezpegaldesleukin, and failure in trials would materially impair partnering prospects and future revenue. The company also faces financing, manufacturing, regulatory and competitive risks typical of clinical-stage biotech, with limited diversification because it currently lacks marketed products. Loss of collaboration revenue or delays in new deals could pressure liquidity and extend dependence on capital markets.
- Clinical failure of rezpegaldesleukinImpact: CriticalLikelihood: Medium
The company states future success is highly dependent on this lead asset, and most investigational drugs fail before approval.
Exposure: Autoimmune disease pipeline
- Loss of collaboration revenueImpact: HighLikelihood: High
Termination of the Eli Lilly collaboration means no collaboration-based revenue for key drug candidates unless new deals are signed.
Exposure - Liquidity and financing riskImpact: HighLikelihood: Medium
The company relies on cash, equity financing and partner funding to support R&D until commercialization or new partnerships.
Exposure: Operating runway and clinical funding
- Regulatory approval riskImpact: HighLikelihood: Medium
Drug development requires lengthy FDA and global review, and approval is not assured even after positive data.
Exposure: All pipeline assets
- Competitive intensityImpact: MediumLikelihood: Medium
Larger pharma and biotech companies may have superior resources, faster development programs and stronger commercialization capabilities.
Exposure: Autoimmune and oncology immunotherapy
- Manufacturing and quality riskImpact: MediumLikelihood: Medium
Contract manufacturers must produce biologics at required quality and scale to support trials and future supply.
Exposure: Clinical supply chain
Accounting
Judgemental itemsUpfront fees and milestones are recognized over time or upon achievement, so timing can shift reported revenue materially.
Impact: Affects license, collaboration and other revenue
Royalty rights previously sold create accounting entries that do not affect cash flow but do affect the income statement.
Impact: Can distort earnings versus operating cash generation
Office and life sciences lease market conditions, sublease assumptions and asset recoverability can drive impairment charges.
Impact: Can materially affect operating results and balance sheet values
Some partner payments may be recorded as reductions of R&D or G&A rather than revenue depending on ASC 808 analysis.
Impact: Changes gross revenue and expense presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Kezar Life Sciences, Inc.
KZR · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Last updated: 24/09/2026